The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
Gilead Files HIV Triplet Biktarvy in Japan, JT Pact Termination Set for Jan. 1
To read the full story
Related Article
- Gilead to Take Over MA for HIV Franchise from JT on Dec. 1
September 3, 2019
- JT to Return Rights to Gilead’s 6 HIV Agents in 2019, Get 63.1 Billion Yen
November 30, 2018
- Gilead Japan Looks to End HIV Pacts with JT as It Seeks Long-Term Growth: Chief
August 28, 2018
- Gilead, JT Start Talks on Terminating Japan HIV Pacts
August 27, 2018
BUSINESS
- Taking on Solid Tumors - 3: J&J to Soon Have 3 Bispecifics in Japan as Rybrevant Gathers Pace
May 30, 2025
- Shingles Heavily Pitched for GPs as It Enters NIP: Intage April Data
May 30, 2025
- Eisai Wins Lenvima Patent Suit in US, Barring Generic to 2036
May 30, 2025
- Bimzelx Now Available as Single-Injection Option: UCB Japan
May 30, 2025
- Mitsubishi Re-Files NeuroDerm’s Parkinson’s Drug in US
May 30, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…